

Sara Gagno

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9516293/sara-gagno-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24 papers	249 citations	8 h-index	15 g-index
28 ext. papers	343 ext. citations	4.4 avg, IF	2.64 L-index

#	Paper	IF	Citations
24	A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. <i>PLoS ONE</i> , 2021 , 16, e0259137	3.7	0
23	A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1185, 122985	3.2	2
22	Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations. <i>Pharmaceutical Research</i> , 2021 , 38, 759-778	4.5	7
21	Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2020 , 149, 30-37	5.3	4
20	A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 187, 113358	3.5	8
19	Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. <i>Frontiers in Pharmacology</i> , 2020 , 11, 36	5.6	5
18	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. <i>PLoS ONE</i> , 2020 , 15, e0228822	3.7	11
17	A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 179, 112949	3.5	5
16	A TGF- β -associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 156, 233-242	4.9	2
15	Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. <i>Pharmacogenomics</i> , 2020 , 21, 995-1010	2.6	
14	Clonal Evolution of c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). <i>Cells</i> , 2019 , 8,	7.9	3
13	New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. <i>Cells</i> , 2019 , 8,	7.9	19
12	rs4143815-, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	3
11	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. <i>PLoS ONE</i> , 2019 , 14, e0225225	3.7	9
10	A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. <i>Clinical Breast Cancer</i> , 2019 , 19, 137-145.e4	3	4
9	Immunogenetics of prostate cancer: a still unexplored field of study. <i>Pharmacogenomics</i> , 2018 , 19, 263-288		2
8	Identification of Novel Somatic Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	6

7	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1101	5.6	4
6	SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder. <i>Neurological Sciences</i> , 2017 , 38, 1233-1240	3.5	21
5	Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. <i>Oncotarget</i> , 2017 , 8, 22863-22875	3.3	6
4	Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. <i>Oncotarget</i> , 2016 , 7, 61970-61987	3.3	26
3	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	10
2	Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. <i>International Journal of Cancer</i> , 2015 , 137, 2971-80	7.5	48
1	Stress-induced anhedonia is associated with an increase in Alzheimer's disease-related markers. <i>British Journal of Pharmacology</i> , 2012 , 165, 897-907	8.6	43